Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
RESEARCH TOOLSreports
ATH Stock Chart & Stats
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume25.42M
Average Volume (3M)8.14M
Market Cap
$82.15M
Enterprise ValueAU$1.43M
Total Cash (Recent Filing)$4.54M
Total Debt (Recent Filing)AU$105.83K
Price to Earnings (P/E)―
Beta2.99
Next Earnings
Feb 26, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding9,127,371,000
10 Day Avg. Volume7,054,369
30 Day Avg. Volume8,142,040
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.74
Price to Sales (P/S)0.00
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alterity Therapeutics News
PremiumCompany Announcements
Alterity Therapeutics Issues 15 Million Unlisted Options to Employees
PremiumCompany Announcements
Alterity Therapeutics to Update on ATH434 Progress in Upcoming Fireside Chat
PremiumCompany Announcements
BNY Mellon Increases Stake in Alterity Therapeutics
PremiumCompany Announcements
Alterity Therapeutics Showcases Promising MSA Treatment Advances
PremiumCompany Announcements
BNY Mellon Increases Stake in Alterity TherapeuticsOptions Prices
Currently, No data available
---
Ownership Overview
0.26%
Insiders
―
Mutual Funds
― Other Institutional Investors
99.74% Public Companies and
Individual Investors
ATH FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is $82.15M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Feb 26, 2026 which is in 236 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 28, 2025. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.001.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate is 0.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 9,127,371,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATH
Alterity Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATH Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $62.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-154.88%
Trailing 12-Months
Asset Growth
-56.88%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. (ATH) is a biotechnology company focused on developing therapeutic products to treat neurodegenerative diseases. The company operates within the biopharmaceutical sector, with its core focus on creating innovative treatments for conditions such as Parkinson's disease and other neurological disorders. Alterity Therapeutics leverages its proprietary drug development platform to discover and advance novel compounds that target the underlying causes of these diseases.
Technical Analysis
Imugene
―
Paradigm Biopharmaceuticals
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―